Trial Profile
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON/LLPC Transplant BRaVE study; Transplant BRaVE
- 01 Dec 2022 Results assessing prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters published in the Leukemia
- 17 Jun 2021 Results of long-term follow-up and biomarker analysis assessing biomarkers relapsed/refractory hodgkin lymphoma patients presented at the 26th Congress of the European Haematology Association
- 09 Apr 2021 This trial has been completed in Denmark, according to European Clinical Trials Database record. (Global end date: 2020-10-23).